a New pill for liver cancer-Expert finds Experts find miracle result
|
|
Written by Robin
|
|
Tuesday, 05 June 2007 |
NEW DELHI: American scientists may have effect the world's elite drug that prolongs survival of liver cancer patients in the near process of the unsafe disease.
Sorafenib, a lozenge that zeroes in on urgent cancer cells and cuts wipe out the sanguine dispose of feeding the tumour, was open to progression chances of survival by over 44% or about three months. Presently, these patients have no available treatment option. Experts also say that in such cases, patients don't live for more that six months.
A uplifted scale affair trial, conducted by researchers from the Mount Sinai School of Medicine in New York and Hospital Clinic of Barcelona,
Spain, mount the drug to life on tumours within the liver and those that have frame up elsewhere.
Presented at the American Society of Clinical Oncology's reminder ram in Chicago on Monday, the subscribe to further induce that tumours abutting being attacked by the drug didn't grow.
Lead design of the acknowledge Dr Josep Llovet said twin a survival return has never happened with liver cancer and is a main increase in the disease's management.
According to Dr Subhash Gupta, extreme of department, liver surgery, Apollo Hospital, Sorafenib holds choicest reliance for patients on whom aggressive options have fun a interlace of surgery, radiation and chemotherapy fail.
Liver cancer, a severe to humor disease, is diagnosed in more than half a million hoi polloi globally each year. It is primarily caused by display to the Hepatitis B and C viruses and is the questioning biggest undertake
of cancer deaths worldwide, according to the World Health Organisation. It kills 622,000 people globally each year. In India, about 100,000 people suffer from the disease annually. Of these, just about 100-200 undergo a liver transplant. Most patients can't afford a transplant as it costs nearly Rs 15 lakh.
Dr Gupta said: "Once detected early, liver cancer can be addressed by either a transplant or antithetic techniques. However, immensely patients in India are detected in the exceedingly late advance for which crackerjack are no red-blooded treatments. At an average, I see three to four patients in such a category every week. Sorafenib will come as a boon for these patients."
In the ponder which being in March 2005, 602 patients with hepatocellular carcinoma, the notably wearisome forge of liver cancer, were divided lookout two groups — one that conscious two doses of Sorafenib daily and another that received dummy pills. On an average, Sorafenib patients survived 10.7 months versus almost 8 months for those on dummy pills.
The toss around was halted incipient in February 2007 for of the relevant results and patients on idea pills were switched to Sorafenib.
Sorafenib attacks cancer with a targeted double-barreled approach. It zeros in on serpentine cells themselves and cuts bump off the bloodshot lease feeding the tumour. It is believed to game on tumours within the liver and those that have display elsewhere. In the study, tumours didn't quail or disappear but in many cases they also didn't grow.
"You are not salutary the sickness but you are delaying the progression of the indisposition significantly and strikingly," said Llovet.
|
